Background Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer.
Introduction
Advanced colorectal cancer is the second most common cause of death from cancer in developed countries, after lung cancer. 1, 2 In the UK, the median age at death from advanced colorectal cancer is 77 years, with 60% of deaths occurring in patients older than 75 years and 42% in those older than 80 years. 3 Frailty, whether or not related to the cancer diagnosis, is frequent in elderly patients.
Standard treatment for advanced colorectal cancer includes palliative chemotherapy, with an expanding range of treatment options. But the evidence supporting these treatments is from clinical trials that underrepresented elderly, frail, and especially frail elderly patients. 4 Several pivotal trials were restricted to patients younger than 75 years; [5] [6] [7] however, even without a formal upper age limit there are several impediments to the recruitment of elderly participants. 8 Reports of outcomes in older 4 or frailer 9 patient subsets within these trials, although interesting, are limited by the fact that the participants were by defi nition suffi ciently robust to have been included in the trials in the fi rst place, whereas many other patients were not.
In 2002, the UK Medical Research Council (MRC) noted that investigators of its fi rst-line trial for advanced colorectal cancer, FOCUS (Fluorouracil, Oxaliplatin, CPT11
[irinotecan]: Use and Sequencing), 10 despite permissive entry criteria and no upper age limit, were recruiting patients with a median age of only 64 years. A survey of investigators showed that the 59 trial oncologists who responded, while recruiting 422 patients into FOCUS, had treated a further 715 patients off -trial during the same period, frequently using reduced-dose or single-agent schedules. The most common reasons cited for noninclusion of technically eligible patients were physicians' concerns about the adverse eff ects of standard-dose treatments, patients' wishes to avoid toxic eff ects, and an assumption that oral therapy would improve quality of life (QoL). We therefore designed FOCUS2 for patients with advanced colorectal cancer who were to receive chemotherapy, but for whom the treating oncologist considered standard full-dose regimens to be unsuitable.
Methods

Study design and patients
Three trial design innovations were used to make FOCUS2 suitable for the frail and elderly population to be studied. First, as is common in non-trial practice, cytotoxic drugs were started at below-standard doses; second, a comprehensive geriatric health assessment was used to identify factors that might aid future selection of patients or regimens; third, alongside standard outcome measures a composite measure of overall treatment utility (OTU) was devised, incorporating objective and subjective measures of benefi t and harm. FOCUS2 was undertaken in 61 UK centres, recruiting patients between January, 2004, and July, 2006 . To enter FOCUS2, the oncologist had fi rst to confi rm, stating reasons, that the patient was in his or her opinion not a candidate for standard full-dose combination therapy. Patients had to have histologically confi rmed colorectal adenocarcinoma, with unidimensionally measurable inoperable advanced or metastatic disease, and a WHO performance status of 2 or better. Patients had to have received no previous systemic chemotherapy for metastases. There was no upper or lower age limit. Previous adjuvant chemotherapy was allowed if completed more than 4 months before randomisation; previous rectal chemo radiotherapy was allowed if completed more than 1 month before randomisation. Patients were not excluded for medical comorbidity unless the condition was so severe as to preclude protocol treatment. However, the following criteria were required: white blood cell count 3×10⁹ per L or greater, platelet count 100×10⁹ per L or greater, serum bilirubin no more than three times the upper limit of normal (ULN), serum transaminases no more than 2·5 times ULN, and glomerular fi ltration rate (GFR) 30 mL per min or greater.
We obtained written consent after verbal explanation and a written information sheet had been given to the patient, with at least 24 h allowed for consideration. Thereafter, but before randomisation, a 117-item comprehensive health assessment (CHA) was done (webappendix pp 1-8 19 and was overseen by an independent Trial Steering Committee. Confi dential interim analyses were reviewed every year by an independent Data Monitoring Committee.
Randomisation and masking
Patients were randomly assigned in a 1:1:1:1 ratio by telephone with a computerised algorithm developed and maintained centrally at the MRC CTU. Randomisation was done by use of the method of minimisation stratifi ed by clinician, WHO performance status, status of primary tumour (resected or not), and age. Treatment allocation was not masked.
Procedures
Treatment was started with standard regimens but at 80% of standard cytotoxic drug doses. Group A received levofolinate 175 mg 2-h intravenous infusion, fl uorouracil 320 mg/m² 5-min intravenous bolus, and fl uorouracil 2240 mg/m² 46-h intravenous infusion. The cycle was repeated every 14 days (FU regimen). This regimen is 80% of the simplifi ed LV5FU2 regimen used in FOCUS. 10, 20 Group B received levofolinate 175 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, fl uorouracil 320 mg/m² 5-min intravenous bolus, and fl uorouracil 1920 mg/m² 46-h intravenous infusion. The cycle was repeated every 14 days (OxFU regimen). This regimen is 80% of the simplifi ed FOLFOX regimen in FOCUS. 10, 20 Group C received capecitabine 1000 mg/m² orally twice per day on days 1-15. The cycle was repeated every 21 days (Cap regimen). This regimen is 80% of the standard licensed schedule. Group D received oxaliplatin 104 mg/m² 2-h intravenous infusion, and capecitabine 800mg/m² orally twice per day on days 1-15. The cycle was repeated every 21 days (OxCap regimen). This regimen is 80% of the standard XELOX regimen. 21 In patients with GFR 30-50 mL per min, oxaliplatin and capecitabine were further reduced by 25%.
Before each cycle, toxicity was scored with common terminology criteria for adverse events (version 3.0). Detailed management of side-eff ects was specifi ed; briefl y, grade 1 and worse eff ects were treated symptomatically; persisting grade 2 and worse toxicity at day 1 of the next treatment cycle incurred a 1-week delay. Cytotoxic doses were reduced by 20% after two delays, or one delay of 2 weeks or more. If grade 2 or worse transaminitis (>2·5 times ULN) developed during capecitabine therapy, treatment was held until recovery.
See Online for webappendix For grade 3 hyperbilirubinaemia (>3 times ULN), all cytotoxic drugs were reduced by 50%. Oxaliplatin was omitted for persistent grade 2 and worse neurological toxic eff ects. Compliance with capecitabine was assessed with patient diary cards and tablet returns.
A senior clinician assessment was scheduled after 6 weeks, when doses could be escalated to 100% of standard doses (an increase of 25% of starting doses), provided that no grade 2 or worse non-haematological toxic eff ects had occurred and that the patient assented. After week 12, radiological response was assessed with Response Evaluation Criteria In Solid Tumors (RECIST) criteria;
22 the clinician assessed whether there had been clinical deterioration in the patient; the CHA was repeated (omitting the comorbidity and mental-state modules) and the patient was asked two additional questions: whether their treatment had been worthwhile and how much it had interfered with activities (webappendix pp [9] [10] [11] [12] [13] .
Thereafter, patients without radiological or clinical evidence of deterioration could continue the same regimen, immediately or after a planned break, with reassessment every 12 weeks. In groups A and C, when progression occurred on the FU or Cap regimens, secondline treatment was considered with the OxFU or OxCap regimens, respectively. Second-line therapy in groups B and D, and third-line therapy in all groups, was at the discretion of the physician.
Statistical analysis
The primary questions in the two factorial comparisons were: does oxaliplatin improve fi rst-line progression-free survival (PFS; For the fi rst question, PFS was defi ned as time from randomisation to fi rst progression or death from any cause, assessed by intention to treat. FOCUS2 was designed to detect a 3-month improvement in median PFS from 6 months to 9 months. For 90% power at the twosided 5% signifi cance level, 460 patients were needed.
For the second question, the primary outcome was QoL improvement. This outcome was defi ned as any increase between baseline and 12 weeks in the EORTC-QLQ-C30 global QoL subscale, reported as a percentage of patients with baseline and 12-week data. In a previous MRC trial, 23 40% of 117 patients reported improved global QoL with this criterion. Paired data from 260 patients (57% of the total) would be suffi cient to detect an increase from 40% to 60%, at the two-sided 5% signifi cance level, with 90% power. PFS was a secondary outcome for this comparison.
Secondary outcome measures for both comparisons included response rate (RR), toxic eff ects, and overall survival (OS). For time-to-event endpoints, Kaplan-Meier curves were produced with patients alive and event-free being censored at the time last seen. Hazard ratios (HRs) and 95% CIs were calculated for each comparison and compared with stratifi ed log-rank tests. RR and toxic eff ects are reported as percentage of assessable patients and compared with χ² tests. We compared QoL improvement with the Mann-Whitney test, which allows for non-normality. Tests for heterogeneity were done for time-to-event outcomes and tests of interaction for all other outcomes.
The novel composite measure OTU was devised to refl ect whether, from the viewpoint of both patient and clinician and with use of both objective and subjective measures, the treatment had been worthwhile. OTU was scored at 12 weeks (webappendix p 14). Briefl y, good OTU indicated no clinical or radiological evidence of disease progression, and no major negative treatment eff ects in terms of toxicity or patient acceptability. Intermediate OTU signifi ed either clinical deterioration but no negative treatment eff ect, or a signifi cant negative treatment eff ect but no clinical deterioration. Poor OTU indicated both clinical deterioration and a major negative treatment eff ect, or death.
We then investigated whether baseline clinicopathological and CHA data can help to predict the probability of a favourable OTU at 12 weeks. Categorical factors and continuous factors with predefi ned cutoff s for categories were treated as categorical, with all other variables regarded as continuous. Univariate analyses were fi rst done, with ordinal logistic regression, to assess patients' baseline characteristics and CHA data in relation to the OTU score at 12 weeks. All variables, irrespective of their univariate result, were then included in a multivariable analysis with backward stepwise ordinal logistic regression. Results are displayed with odds ratios (ORs) to show the odds of a worse outcome, with eff ect size (Z value) and statistical signifi cance (p value).
This study is registered, number ISRCTN21221452.
Role of the funding source
The sponsor of the study was the MRC which, as the parent body of the MRC CTU, was involved in the design, conduct, and analysis of the trial. The manufacturers of the drugs used in the study were not involved in the research. The corresponding author had full access to the data and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. 411 of 459 (90%) patients Figure 1 shows the trial profi le. 411 of 459 (90%) patients had died at the time of fi nal analysis. had died at the time of fi nal analysis. Baseline characteristics were well balanced between groups (table table 1 419 (91%) patients were alive and receiving treatment 6 weeks after starting treatment, and so were eligible for discretionary escalation to 100% of standard doses (table table 2 ). Of these patients, 154 (37%) had dose escalation. Dose escalation was more frequent in patients allocated single agent than combination therapy (p=0·01). Only 60 (14% of all patients starting treatment) sustained the higher dose to 12 weeks (table 2) . 146 (33%) patients sustained the 80% standard starting dose to 12 weeks, whereas 215 (49%) needed a further dose reduction or stopped (table 2) . Capecitabine compliance, assessed by tablet returns, was greater than 97% in the Cap (group C) and OxCap (group D) regimens (data not shown).
Results
At the time of analysis 445 (97%) patients had had a PFS event (fi gure fi gure 2A). PFS, measured by intention to treat, was the primary outcome measure for the factorial comparison of treatment with or without oxaliplatin; this comparison suggested some benefi t of oxaliplatin but the fi nding was not signifi cant (fi gure 2A ; table table 3) . Factorial comparison of fl uorouracil versus capecitabine showed no eff ect on PFS (fi gure 2B; table 3).
Paired baseline and 12-week QoL data were available in 247 patients, with similar numbers in each group (table 3) . QoL improvement was the primary outcome measure for the factorial comparison of fl uorouracil versus capecitabine; this comparison showed no diff erence between groups, with more than half of assessable patients reporting improved QoL in both groups (table 3) . Factorial comparison of treatment with and without oxaliplatin was suggestive of a detrimental eff ect with oxaliplatin regimens (table 3) .
RR was assessed with RECIST criteria but only at 12 weeks after randomisation. In the factorial com parisons, we recorded good evidence that oxaliplatin increased the RR (complete response plus partial response) and the rate of disease control (stable disease, complete response, and partial response; table 3). We noted no evidence that the substitution of fl uorouracil with capecita bine had an eff ect on response or disease control (table 3) .
Factorial analysis showed no evidence of OS benefi t with fi rst-line oxaliplatin (fi gure 2C). Similarly, factorial analysis showed no diff erence in OS between fl uorouracil and capecitabine (fi gure 2D).
440 (96%) patients had complete data for toxic eff ects. The overall risk of having a grade 3 or worse event during the fi rst 12 weeks ranged from 27% of assessed patients (29 of 109) with the FU regimen to 43% (47 of 110) with the OxCap regimen (table 4). In the factorial comparisons, the use of oxaliplatin did not signifi cantly increase the overall risk of toxic eff ects, but we noted evidence of increased rates of diarrhoea, neurosensory toxicity, nausea, vomiting, and neutro penia, and a lower rate of hand-foot syndrome compared with no use of oxaliplatin (table 4) . Compared with fl uorouracil, capecitabine increased the overall risk of a grade 3 or worse event (p=0·03), and was specifi cally associated with increased rates of nausea, vomiting, diarrhoea, anorexia, and hand-foot syndrome.
438 (95%) patients had complete data to allow scoring of OTU at 12 weeks, of whom 182 (42%) was strongly associated with improved PFS and OS (both p<0·0001, log-rank trend test; data not shown). In the factorial comparisons, allocation to receive oxaliplatin was associated with better OTU (p=0·003), but we recorded no signifi cant diff erence in OTU with fl uorouracil or capecitabine (table 3) .
Univariate analysis was done with baseline clinicopathological variables, CHA variables, and treatment allocation (fi gure fi gure 3). The strongest predictors of 12-week OTU were: WHO performance status, white blood cell count, EQ5D QoL score, overall symptom score, and allocation to oxaliplatin (all p<0·01; fi gure 3). Tests for interaction between the two treatment factors showed no evidence of an interaction (data not shown). FU=simplifi ed LV5FU2 regimen of levofolinate, bolus fl uorouracil, and 46-h infusion of fl uorouracil, repeated every 2 weeks. OxFU=oxaliplatin plus FU. Cap=capecitabine. OxCap=oxaliplatin plus Cap. HFS=hand-foot syndrome. We recorded no evidence of interaction between the two treatment factors (p=0·209; data not shown).
Multivariable analyses (table table 5 ) produced a potentially predictive model based on overall symptom score, presence of liver plus extrahepatic metastases, and treatment. WHO performance status and age were included for clinical relevance. On the basis of this model, a 70-year-old patient with performance status of 1, with both liver and extrahepatic metastases, whose overall symptom score is 60, treated with single-agent fl uoropyrimidines, has a 61% (95% CI 45-76) probability of a poor OTU and only a 12% (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) probability of a good OTU. Conversely, an 80-year-old patient with performance status of 1 and a symptom score 0 and either extrahepatic-only or liver-only disease, treated with combination chemotherapy, has a 66% (56-77) probability of a good OTU and only 10% (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) probability of a poor OTU.
Discussion
This is the largest randomised controlled trial so far to have selectively recruited frail and elderly patients with advanced colorectal cancer (panel). With use of reduced starting drug doses, adapted for this population, combination chemotherapy including oxaliplatin seems, on balance, preferable to single-agent fl uoropyrimidines, although the primary endpoint of PFS was not met. We did not, however, detect any advantage of capecitabine compared with fl uorouracil.
FOCUS2 successfully recruited an elderly and frail population into a large national trial. Indeed, the trial proved so popular with patients and clinicians that it recruited well ahead of target, showing that age and frailty need not be barriers to research. The decision to start treatments at 80% of standard doses, although arbitrary, mimics common non-trial practice in frail elderly patients. Generally moderate rates of toxic eff ects and good rates of improvement in QoL in all groups would seem to support this strategy, whereas the relatively low uptake of escalation at 6 weeks, and the fact that only 14% of all patients sustained full-dose therapy to 12 weeks, supports the notion that the trial population was unsuited for full-dose therapy.
We introduced a novel composite endpoint, OTU, to assess the outcome of palliative chemotherapy, and explored the use of objective baseline evaluation to estimate the likelihood of a good or poor outcome with treatment. When confi rmed and refi ned with further studies, this approach could potentially provide valuable guidance for doctors and patients in the diffi cult decisions between active or symptomatic care or, potentially, between active regimens. The interpretation of clinical trials, especially trials of palliative chemotherapy, often needs subjective synthesis of the objective data. Measures of effi cacy are weighed against toxic eff ects, convenience, and other variables before deciding which treatment is best. For FOCUS2 we developed a simple composite endpoint of treatment outcome, OTU, to refl ect both the doctor's question: "In retrospect, am I glad I off ered this treatment?"; and the patient's question: "Am I glad I accepted it?". OTU combines clinical effi cacy ("Is my patient alive without disease progression?"), clinical tolerability ("Did we avoid causing major harm?"), and patient opinion ("Was my treatment worthwhile and acceptable?"). We encourage other research groups to adopt and refi ne this patient-centred approach.
OTU proved useful in comparison of treatment groups, particularly when conventional endpoints were divergent. The addition of oxaliplatin signifi cantly increased RR and suggested some improvement in PFS, although this Interaction between the two treatment factors was assessed (Z=-1·26, p=0·209). OTU=overall treatment utility. *This odds ratio relates to a 10-point change in the overall symptom score. 4 or from trials of full-dose chemotherapy in selected fi t elderly patients. 24 These analyses show that elderly patients selected for full-dose treatments achieve survival times similar to younger patients on the same treatments; however, they represent only a small and highly selected proportion of the elderly cancer population. Interpretation FOCUS2 adds to the totality of evidence because it is the fi rst large randomised trial in colorectal cancer to have been designed specifi cally for frail elderly patients and to relate objective baseline measures of geriatric fi tness with patient-related outcomes of chemotherapy. Survival, at a median of 11 months, is noticeably shorter than in contemporaneous standard trials. For example, during overlapping recruitment periods two other MRC trials, FOCUS and COIN, were running at many of the same centres as FOCUS2, accruing patients with a median age of 63 years, more than 90% of whom had WHO performance status 0-1, with median survival of 14-17 months. 10, 25, 26 Meanwhile, in France, a selective trial using more intensive therapy achieved median survival of more than 20 months. 27 However, a meta-analysis of 6286 patients in nine trials, including FOCUS and the French trial, shows that frailty is a dominant negative prognostic factor, with median survival of only 8·5 months in the subpopulation with WHO performance stats of 2.
9 This fi nding is entirely consistent with the survival recorded in FOCUS2, in which 134 of 459 (29%) patients were of performance status 2, and 324 of 459 (71%) were regarded as too frail to receive standard therapy (table 1) .
fi nding was not signifi cant; however, it also increased some toxic eff ects and seemed to negatively aff ect global QoL. So overall, was treatment with oxaliplatin worthwhile? OTU showed unequivocal evidence of overall benefi t with oxaliplatin (table 3; fi gure 3).
For the second factorial question, capecitabine has previously been shown to be non-inferior to fl uorouracil, 28 and oral therapy is generally thought to be preferred by patients, either because of its convenience or because it is assumed to have low toxicity. However, although analysis of PFS and RR confi rmed capecitabine's effi cacy, we recorded increased toxicity and no evidence of improved QoL. And despite including a measure of whether treatment interferes with patients' normal activities, the OTU scores for patients receiving capecitabine were not superior; indeed, they tended to favour fl uorouracil, although this diff erence was not signifi cant (table 2B; fi gure 3A).
Guidelines from the US National Comprehensive Cancer Network recommend use of a comprehensive geriatric assessment (CGA) to guide decision making when considering chemotherapy in elderly patients. 29, 30 However, there currently exists no evidence-based method to combine the many data items generated by the CGA into one decision about whether to off er chemotherapy, or which regimen to use. The 117-item geriatric assessment used in FOCUS2 was feasible in the oncology clinic, and we have started to identify which elements are of greatest value in prediction of the use of palliative chemotherapy. To develop a working predictive model will need cross-validation with other studies, but this approach off ers the potential to better inform oncologists' discussions with patients. For example, a high predicted probability of a good OTU would support encouragement for chemotherapy; conversely, a high predicted probability of poor OTU (eg, in a patient with a high symptom score and widespread metastases) might help the oncologist and patient to consider with confi dence the option of non-chemotherapy-based care.
New therapies now present new opportunities to develop treatments with few toxic eff ects for frail elderly patients with advanced colorectal cancer. For example, investigators of the AGITG MAX trial, 31 undertaken in patients of median age 68 years, reported signifi cantly improved PFS without signifi cant extra toxicity from the addition of bevacizumab to single-agent capecitabine. We encourage investigators to continue to design trials using appropriate low-toxicity treatments and patientcentred assessment to expand the evidence base in this important specialty.
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